180 Life Sciences Stock (NASDAQ:ATNF)

Revenue Ownership Financials Chart

Previous Close

$1.47

52W Range

$1.16 - $17.75

50D Avg

$1.98

200D Avg

$2.09

Market Cap

$4.51M

Avg Vol (3M)

$466.81K

Beta

0.25

Div Yield

ATNF Company Profile

1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Jun 27, 2017

Website

ATNF Performance

ATNF Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	-	-	-
Operating Income	$-13.48T	$-17.90M	$-15.64M
Net Income	$-19.94T	$-38.73M	$-20.32M
EBITDA	$-13.48T	$-17.79M	$-14.76M
Basic EPS	$-52.59	$-20.38	$-12.96
Diluted EPS	$-52.59	$-20.38	$-12.96

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

Ticker	Company
ZVSA	ZyVersa Therapeutics, Inc.
PHIO	Phio Pharmaceuticals Corp.
CNSP	CNS Pharmaceuticals, Inc.
IMMX	Immix Biopharma, Inc.
SONN	Sonnet BioTherapeutics Holdings, Inc.
CDIO	Cardio Diagnostics Holdings, Inc.
ZURA	Zura Bio Limited
ENVB	Enveric Biosciences, Inc.
PALI	Palisade Bio, Inc.